Acción BTAX BIOSTAX CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Biostax Corp.

Acciones

BTAX

US45252A3059

Mercado cerrado - OTC Markets
Otros sitios de cotización
 15:30:09 20/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0335 USD -4,29 % Gráfico intradía de Biostax Corp. -4,29 % -54,11 %
20/05 Biostax Corp. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
16/04 Biostax Corp. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
Biostax Corp. Appoints Craig Suro as a Director
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
Immune Therapeutics, Inc. will Change its Name to Biostax Corp
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
Immune Therapeutics, Inc. Announces CEO Changes
Immune Therapeutics, Inc. Announces Management Changes
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BTAX
  4. Noticias Biostax Corp.
  5. Otros idiomas